Newly identified breast luminal progenitor and gestational stem cell populations likely give rise to HER2-overexpressing and basal-like breast cancers

• Published in: Discover. Oncology Vol. 13; no. 1; p. 38
• Main Authors: McMullen, James R. W., Soto, Ubaldo
• Format: Journal Article
• Language: English
• Published: New York Springer US 28-05-2022; Springer
• Subjects: Basal-like breast cancer; Breast cancer; Breast neoplasms; Cancer Research; HER2 breast cancer; Internal Medicine; Mammary gland development; Medicine; Medicine & Public Health; Molecular Medicine; Oncology; Radiotherapy; Surgical Oncology; Breast cancer; Breast neoplasms; Basal-like breast cancer; Mammary gland development; HER2 breast cancer
• ISSN: 2730-6011; 2730-6011
• DOI: 10.1007/s12672-022-00500-6

Breast Cancer (BrC) is a common malignancy with genetically diverse subtypes. There is evidence that specific BrC subtypes originate from particular normal mammary cell populations. However, the cell populations that give rise to most BrC subtypes are unidentified. Several human breast scRNAseq datasets are available. In this research, we utilized a robust human scRNAseq dataset to identify population-specific marker genes and then identified the expression of these marker genes in specific BrC subtypes. In humans, several BrC subtypes, HER2-enriched, basal-like, and triple-negative (TN), are more common in women who have had children. This observation suggests that cell populations that originate during pregnancy give rise to these BrCs. The current human datasets have few normal parous samples, so we supplemented this research with mouse datasets, which contain mammary cells from various developmental stages. This research identified two novel normal breast cell populations that may be the origin of the basal-like and HER2-overexpressing subtypes, respectively. A stem cell-like population, SC, that expresses gestation-specific genes has similar gene expression patterns to basal-like BrCs. A novel luminal progenitor cell population and HER2-overexpressing BrCs are marked by S100A7, S100A8, and S100A9 expression. We bolstered our findings by examining SC gene expression in TN BrC scRNAseq datasets and S100A7-A9 gene expression in BrC cell lines. We discovered that several potential cancer stem cell populations highly express most of the SC genes in TN BrCs and confirmed S100A8 and A9 overexpression in a HER2-overexpressing BrC cell line. In summary, normal SC and the novel luminal progenitor cell population likely give rise to basal-like and HER2-overexpressing BrCs, respectively. Characterizing these normal cell populations may facilitate a better understanding of specific BrCs subtypes.